about
External beam radiotherapy in the management of differentiated thyroid cancerGeographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trialsA recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.Cancer of the anal canal.Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials.PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastaThe role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy.Outcome of T1N0M0 squamous cell carcinoma of the larynx treated with short-course radiotherapy to a total dose of 50 Gy in 16 fractions: the Birmingham experience.The Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Cancer after Radical Chemoradiotherapy: a Single Institution Experience.Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer.Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck.Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer?Revised radiobiological modelling of the contribution of synchronous chemotherapy to the rate of grades 3-4 mucositis in head and neck cancer.Can protons or altered fractionation decrease neurotoxicity after chemoradiation in head and neck cancer?Dedifferentiated adenoid cystic carcinoma of the nasopharynx: a rare entity of head and neck cancer.Initial Efficacy of Hypofractionated Accelerated Chemo-Tomotherapy® for Nasopharyngeal Carcinoma.Early radiotherapy related morbidityRetrospective study of acute toxicity following short-course preoperative radiotherapyImpaired postoperative neutrophil leucocytosis and acute complications following short course preoperative radiotherapy for operable rectal cancerClear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgeryLate toxicity after short course preoperative radiotherapy and total mesorectal excision for resectable rectal cancerImproving outcomes in head and neck cancerHypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neckMulticentre prospective audit of surgical outcomes and acute complications following short course pre-operative radiotherapy for resectable rectal cancerHypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancerImproved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effectsCarboplatin and hypofractionated accelerated radiotherapy: a dose escalation study of an outpatient chemoradiation schedule for squamous cell carcinoma of the head and neckRadiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancerModeling the contribution of synchronous chemotherapy to the rate of grade 3 and 4 mucositis in locally advanced squamous cell carcinoma of the head and neckVariation in volume definition between UK head and neck oncologists treating oropharyngeal carcinomaHypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neckModels of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancerIs 5-year feeding tube dependency a mixed consequential late effect? In regard to Beitler et alLinear accelerator stereotactic radiosurgery for vestibular schwannomas: a UK seriesDoes Dose to an Oral Mucosa Organ at Risk Predict the Duration of Grade 3 Mucositis after Intensity-modulated Radiotherapy for Oropharyngeal Cancer?Hypofractionated Accelerated Chemoradiation for Oropharyngeal Cancer and the 2016 Royal College of Radiologists' Fractionation Guidelines
P50
Q28206777-A3398D4A-45B9-4901-AE42-FC16120041AEQ31036080-52085984-6FB3-4818-B23D-D7627CD9FD3AQ35121627-CD2B56B5-C337-4EE8-AF1C-915B2086E306Q35683341-809E0AD6-B2D1-4018-9CED-9E7CF2555716Q36263852-F3C93C49-61F4-47E8-9375-EFE56DA487C1Q36346834-450C4A60-35BB-429F-BF2E-219D2B569207Q36407111-0DD5EB68-7072-4EE9-A3AC-EAEA975D5007Q37450021-5CDE2133-DACD-4F34-8CDA-1DEAF56B6A49Q38639075-2C91418A-80D2-41C0-9E93-3FBE346743A9Q39839391-186530E1-96DB-43A2-84E1-3A99655D3FDBQ43519852-D1473CB8-5F7A-41DB-AA07-1B081D50079AQ44615768-23938AEA-D552-48C8-B4BF-FBBA46181BA4Q45399446-2C2968F8-C41B-48EE-83CD-420B11833606Q50448469-71B075E8-781A-4559-B0C9-35B0CE457E04Q52981770-2D285142-A5F3-4B60-8AAA-2E3FCA2A7F72Q53979838-43F98BDF-3150-4EEF-8F6E-679EA1FED1BCQ60632740-72992A7C-3142-4ABE-A8D0-95E13E8B4D33Q60632742-37949E98-1B7E-40A7-8633-9BB01EBBEC43Q73118554-80B41749-DFA4-4348-A0B1-0A52DA1181C5Q73628851-1019F26F-6DEA-48EE-9ECB-9A76A097A660Q73820234-DAE48582-A818-4F7B-A904-ED17179212D6Q73820254-71CD8E85-D604-45BC-A547-A8A85AC7BBC8Q79620876-0D427085-D134-455E-815B-4D106C02FAEEQ81162684-E308133F-235F-4C6F-9DFA-1C233A9B28D9Q81895190-31A18021-5657-4597-8686-9E1621972C2DQ82550264-46434CEB-5736-46DF-BD41-C8613FC3AF9CQ82550299-25B93B21-E701-4015-8543-E7525700FC2CQ84067022-2CF1A77D-C932-43B6-BC4A-3747D1B6581AQ84439508-93E8DA05-8878-4908-A84C-9D1D095B1F73Q84703638-50C0647D-8DE1-4965-A3D0-89D99721238BQ85072182-03AEEF61-0A2B-48D6-8DBC-9AF62783AB70Q86492235-EE9353DF-3CD9-4F4F-AE90-4155541B8E93Q86629472-5E436DD1-78B3-4A28-88F9-942BE416797FQ87456802-B67BFF3A-EA13-48ED-AABA-5A1F0104B0BCQ88262495-6D7699B9-155E-43FF-B231-48DB9AF763DAQ89357292-7D0B2DAD-28CA-4E50-B27A-9F18818E84A1
P50
description
researcher ORCID ID = 0000-0001-8848-4916
@en
name
Andrew Hartley
@ast
Andrew Hartley
@en
Andrew Hartley
@es
Andrew Hartley
@nl
type
label
Andrew Hartley
@ast
Andrew Hartley
@en
Andrew Hartley
@es
Andrew Hartley
@nl
prefLabel
Andrew Hartley
@ast
Andrew Hartley
@en
Andrew Hartley
@es
Andrew Hartley
@nl
P1153
7102081014
P31
P496
0000-0001-8848-4916